Home
Clinical Trials
Phase II Study With Cabozanti...

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC

Last Updated: 2019-10-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-07

Study Completion Date

2022-08-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is aimed to explore the antitumor activity, safety and efficacy profile of cabozantinib in pretreated, advanced RET-rearranged non-small cell lung cancer patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation

NCT03911193

Non-Small Cell Lung Cancer

UNKNOWN PHASE2

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

NCT01154140

Non Squamous Lung Cancer

COMPLETED PHASE3

Cabazitaxel in Relapsed and Metastatic NSCLC

NCT01852578

NSCLC

COMPLETED PHASE2

Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer

NCT01500720

Small Cell Lung Cancer

COMPLETED PHASE2

A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer

NCT00152477

Carcinoma Non-Squamous Non-Small-Cell Lung Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

Intervention Model

SINGLE_GROUP

Single-arm, ope label clinical trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cabozantinib

Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.

Group Type EXPERIMENTAL

Cabozantinib 20 MG

Intervention Type DRUG

Cabozantinib 40 MG

Intervention Type DRUG

Cabozantinib 60 MG

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cabozantinib 20 MG

Intervention Type DRUG

Cabozantinib 40 MG

Intervention Type DRUG

Cabozantinib 60 MG

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CABOMETYX CABOMETYX CABOMETYX

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Locally advanced, relapsed or metastatic non-small cell lung cancer - stage IIIB/IV according to 7th International Association for the Study of Lung Cancer (IASLC) classification
2. Ability to understand and willingness to sign informed consent prior to initiation of any study procedures.
3. Pathologically (histology or cytology) confirmed diagnosis of non- small cell lung carcinoma.
4. RET gene rearrangement by local laboratory analysis with an approved standard method (FISH or Next Generation Sequencing Panel). An archival tumor sample must be available for central laboratory confirmation.
5. Male or female and = 18 years of age
6. Life expectancy = 12 weeks
7. Have progressed after or during at least one standard anticancer treatment
8. Have measurable disease as per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1); clear radiological evidence of disease progression after first-line therapy must be documented; no previous radiotherapy on the only site of measurable or evaluable disease, unless that site had subsequent evidence of progression
9. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1
10. Subjects must have adequate organ function including the following:

* Absolute neutrophil count \> 1.5 x 10\^9/L
* Platelet count \> 100 x 10\^9/L
* Haemoglobin \> 90 g/L
* ALT \< 2.5 times the upper limit of normal (ULN)
* AST \< 2.5 times ULN
* Total bilirubin \<1.5 times ULN
* Creatinine \<1.5 times ULN concurrent with creatinine clearance \> 50 ml/min (measured or calculated by Cockcroft and Gault equation, confirmation of creatinine clearance is only required when creatinine is \> 1.5 times ULN)
* Lipase \< 2.0 times the upper limit of normal (ULN)

Exclusion Criteria

12. Recovered (i.e., = Grade 1 toxicity) from effects of prior anticancer therapy, except alopecia
13. No radiologic or clinical evidence of acute or chronic pancreatitis
14. For Females: must be postmenopausal (defined as amenhorrea = 12 consecutive months) before the screening visit, or are surgically sterile. If they are of childbearing potential, a negative serum pregnancy test obtained within 3 days before starting study treatment has to be documented; furthermore, patients must agree to adopt 2 effective methods of contraception, at the same time, from the time of signing the informed consent form (ICF) through 4 months after the last dose of study drug.
15. For Males: even if surgically sterilized (i.e. post-vasectomy status) agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug.
16. Ability to comply with protocol requirement.

1. Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before randomization. Systemic treatment with radionuclides within 6 weeks before randomization. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
2. Previous treatment with cabozantinib.
3. Gastrointestinal disorders likely to interfere with absorption of the study drug.
4. Subjects with gastrointestinal disorders associated with a high risk of perforation of fistula formation.
5. Subjects with active peptic ulcer or with a history of clinically ¿significant GI bleeding within 6 months before the first dose of study treatment.
6. Patients requiring full-dose anticoagulation therapy any time prior to enrollment.
7. Current use of aspirin, clopidogrel, ticlopidine.
8. Patients with tumors invading major pulmonary vessels and/or with cavitating pulmonary lesions.
9. Major surgery within the last four weeks. Complete wound healing from major surgery must have occurred 1 month before randomization and from minor surgery at least 10 days before randomization. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.
10. Subjects with clinical or radiological signs of pulmonary hemorrhage within 3 months before the first dose of study treatment.
11. Symptomatic CNS or leptomeningeal lesions, not previously treated with radiotherapy.

Untreated central nervous system (CNS) or leptomeningeal metastases are allowed if asymptomatic. Patients with symptomatic CNS or leptomeningeal lesions will be allowed to participate in this study if previously treated with radiotherapy and on stable dose of corticosteroids and/or anticonvulsants for \> 10 days or not requiring such medication.

Radiotherapy must have been completed a minimum of 4 weeks prior to registration, and patients must have recovered from AEs related to radiotherapy to \< grade 1 (except alopecia).
12. History of congenital platelet function defect.
13. Patient unable to swallow tablets
14. Corrected QT interval greater than 500 ms (Fridericia formula)
15. Clinically significant, uncontrolled heart diseases:

* Unstable angina within 6 months prior to screening
* Myocardial infarction within 6 months prior to screening
* History of documented congestive heart failure
* Uncontrolled hypertension defined by a Systolic Blood Pressure , with or without antihypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening
* Ventricular arrhythmias, Supraventricular and nodal arrhythmias not controlled with medication
* Congenital history of QT syndrome.
16. Diagnosed with or treated for another malignancy within 3 years before the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type may be enrolled in the study if they have undergone complete resection and no evidence of active disease is present.
17. Any type of systemic anticancer agent within 3 weeks of first dose of study treatment, or within 5 half- lives of the agent whichever is shorter (subjects on LHRH or GnRH agonists may be maintained on these agents)
18. Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
19. Rare hereditary problems of

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Andrea Ardizzoni

Professor/MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

OU di Oncologia Medica- Azienda ospedaliero-Universitaria S. Orsola Malpighi

Bologna, , Italy

Site Status RECRUITING